ArticlePharmaceuticals (Basel, Switzerland)2023

A Phase 2a, Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy and Safety of ALS-L1023 in Non-Alcoholic Fatty Liver Disease.

Gi-Ae Kim et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.